Maintelyte (Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride, Glucose, Sodium Acetate Trihydr)

The active ingredients—magnesium chloride, potassium chloride, sodium chloride, glucose, and sodium acetate—are delivered directly into the bloodstream. They increase plasma osmolarity, expand extracellular fluid volume, and replenish specific electrolytes, while glucose supplies an immediate energy source, collectively correcting dehydration and electrolyte deficits.

The prescribed dose of Maintelyte is determined by the treating clinician based on the patient’s fluid loss, electrolyte status, weight, and clinical condition. Healthcare professionals calculate the appropriate volume and infusion rate to safely achieve fluid and electrolyte replacement.

Safety data for Maintelyte in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Maintelyte, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Maintelyte differs from plain saline or dextrose solutions by containing a balanced mix of magnesium, potassium, sodium, acetate, and glucose, making it suitable for patients who need both volume expansion and specific electrolyte repletion. Other IV fluids may lack these electrolytes or provide different osmolarities, influencing the choice based on clinical needs.

Maintelyte should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, inspect for particulate matter or discoloration and allow the product to reach room temperature if required for administration.

Maintelyte is administered intravenously as a solution for injection. The infusion rate and total volume are set by the prescriber, often using an infusion pump or controlled drip, with continuous monitoring of the patient’s vital signs and electrolyte levels during administration.

Serious risks include hypermagnesemia, hyperkalemia, severe allergic reactions, metabolic acidosis, and fluid overload leading to pulmonary edema. These events require immediate medical attention and may be mitigated by careful patient assessment and monitoring during therapy.

Maintelyte should be avoided in patients with known hypersensitivity to any of its components, severe renal impairment where electrolyte excretion is compromised, uncontrolled hyperkalemia, or conditions predisposing to fluid overload unless closely monitored by a healthcare professional.